Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab in Rheumatoid Arthritis (CREDO 1)
NCT02760368Phase 3Completed
- Sponsor
- R-Pharm
- Start
- May 2016
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of olokizumab in rheumatoid arthritis (RA), sponsored by R-Pharm. Started May 2016; status: completed.
02
Drugs
olokizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02760368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02760368.